PT  - JOURNAL ARTICLE
AU  - Berndt, Jason D.
AU  - Duffy, Fergal J.
AU  - D’Ascenzo, Mark D.
AU  - Miller, Leslie R.
AU  - Qi, Yijun
AU  - Whitney, G. Adam
AU  - Danziger, Samuel A.
AU  - Vachani, Anil
AU  - Massion, Pierre P.
AU  - Deppen, Stephen A.
AU  - Lipshutz, Robert J.
AU  - Aitchison, John D.
AU  - Smith, Jennifer J.
TI  - Cell-based assay for blood-based diagnostics enhances prediction of lung cancer in patients with lung nodules
AID  - 10.1101/2024.11.04.24316585
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.11.04.24316585
4099  - http://medrxiv.org/content/early/2024/11/05/2024.11.04.24316585.short
4100  - http://medrxiv.org/content/early/2024/11/05/2024.11.04.24316585.full
AB  - The iCAP is a tool for blood-based diagnostics that addresses the low signal-to-noise ratio of blood biomarkers by using cells as biosensors. The assay exposes small volumes of patient serum to standardized cells in culture and classifies disease by AI analysis of gene-expression readouts from the cells. It simplifies the complexity of blood into a concise readout in a scalable cell-based assay. We developed the LC-iCAP as a rule-out test for nodule management in CT-based lung cancer screening. The assay achieved an AUC of 0.63 (95% CI 0.50-0.75) in retrospective-blind-temporal validation. When integrated with CT data after validation, it demonstrated potential to reduce unnecessary follow-up procedures by significantly outperforming the Mayo Clinic model with 90% sensitivity, 67% specificity and 95% NPV using an estimated 25% prevalence. Analytical validation established LC-iCAP reproducibility and identified unwanted variation from long-term serum storage suggesting a prospective study design could enhance performance.Competing Interest StatementCompeting interests: RJL, JJS, JDB, GAW, MDD, and YQ are current and/or past employees of PreCyte and have equity interests in the company. JDA and RJL serve as board members with equity interests in PreCyte. LRM and SAD also have equity interests in PreCyte. FJD acts as a consultant and/or has performed contracted work for PreCyte. JJS, RJL, JDA, JDB, MDD, GAW, and FJD have filed patent applications related to the compositions, methods, kits, and processes described in this manuscript in the US and in foreign jurisdictions. SD and AV declare no conflicts of interest.Funding StatementResearch reported in this publication was supported by the National Cancer Institute (NCI) and National Institute of Aging (NIA) of the National Institutes of Health (NIH) under Award Numbers R43CA203455, R44CA203455 and R44AG051282 to PreCyte, the National Institute of Environmental Health Sciences (NIEHS) of the NIH under Award Number P30ES013508 to the University of Pennsylvania, and the NCI of the NIH under award number P30CA068485 and NCI-U01CA152662 to Vanderbilt University. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:WCG IRB gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are either contained in the manuscript or supplementary tables and figures except for complete Raw and processed RNAseq data. Raw and processed RNAseq data have been submitted to GEO repository and will be publicly available after peer review.AUCarea under the ROC curveCTcomputed tomographyDEGdifferentially expressed geneDMOGdimethyloxalylglycineGSEAgene set enrichment analysisiCAPindicator cell assay platformNPVnegative predictive valueROCreceiver operator characteristicMCEDmulti-cancer early detection